313 related articles for article (PubMed ID: 26065842)
1. Omecamtiv Mecarbil, a Cardiac Myosin Activator, Increases Ca2+ Sensitivity in Myofilaments With a Dilated Cardiomyopathy Mutant Tropomyosin E54K.
Utter MS; Ryba DM; Li BH; Wolska BM; Solaro RJ
J Cardiovasc Pharmacol; 2015 Oct; 66(4):347-53. PubMed ID: 26065842
[TBL] [Abstract][Full Text] [Related]
2. Long-Term Biased β-Arrestin Signaling Improves Cardiac Structure and Function in Dilated Cardiomyopathy.
Ryba DM; Li J; Cowan CL; Russell B; Wolska BM; Solaro RJ
Circulation; 2017 Mar; 135(11):1056-1070. PubMed ID: 28104714
[TBL] [Abstract][Full Text] [Related]
3. Omecamtiv mecarbil: a new cardiac myosin activator for the treatment of heart failure.
Liu LC; Dorhout B; van der Meer P; Teerlink JR; Voors AA
Expert Opin Investig Drugs; 2016; 25(1):117-27. PubMed ID: 26587768
[TBL] [Abstract][Full Text] [Related]
4. Dilated cardiomyopathy mutant tropomyosin mice develop cardiac dysfunction with significantly decreased fractional shortening and myofilament calcium sensitivity.
Rajan S; Ahmed RP; Jagatheesan G; Petrashevskaya N; Boivin GP; Urboniene D; Arteaga GM; Wolska BM; Solaro RJ; Liggett SB; Wieczorek DF
Circ Res; 2007 Jul; 101(2):205-14. PubMed ID: 17556658
[TBL] [Abstract][Full Text] [Related]
5. Familial dilated cardiomyopathy mutations uncouple troponin I phosphorylation from changes in myofibrillar Ca²⁺ sensitivity.
Memo M; Leung MC; Ward DG; dos Remedios C; Morimoto S; Zhang L; Ravenscroft G; McNamara E; Nowak KJ; Marston SB; Messer AE
Cardiovasc Res; 2013 Jul; 99(1):65-73. PubMed ID: 23539503
[TBL] [Abstract][Full Text] [Related]
6. Cardiac myosin light chain phosphorylation and inotropic effects of a biased ligand, TRV120023, in a dilated cardiomyopathy model.
Tarigopula M; Davis RT; Mungai PT; Ryba DM; Wieczorek DF; Cowan CL; Violin JD; Wolska BM; Solaro RJ
Cardiovasc Res; 2015 Jul; 107(2):226-34. PubMed ID: 26045475
[TBL] [Abstract][Full Text] [Related]
7. Dose-dependent augmentation of cardiac systolic function with the selective cardiac myosin activator, omecamtiv mecarbil: a first-in-man study.
Teerlink JR; Clarke CP; Saikali KG; Lee JH; Chen MM; Escandon RD; Elliott L; Bee R; Habibzadeh MR; Goldman JH; Schiller NB; Malik FI; Wolff AA
Lancet; 2011 Aug; 378(9792):667-75. PubMed ID: 21856480
[TBL] [Abstract][Full Text] [Related]
8. Perspectives of a myosin motor activator agent with increased selectivity.
Nánási P; Komáromi I; Almássy J
Can J Physiol Pharmacol; 2018 Jul; 96(7):676-680. PubMed ID: 29792814
[TBL] [Abstract][Full Text] [Related]
9. Omecamtiv Mecarbil: A Myosin Motor Activator Agent with Promising Clinical Performance and New in vitro Results.
Nanasi P; Komaromi I; Gaburjakova M; Almassy J
Curr Med Chem; 2018; 25(15):1720-1728. PubMed ID: 29278207
[TBL] [Abstract][Full Text] [Related]
10. Direct Myosin Activation by Omecamtiv Mecarbil for Heart Failure with Reduced Ejection Fraction.
Psotka MA; Teerlink JR
Handb Exp Pharmacol; 2017; 243():465-490. PubMed ID: 28315072
[TBL] [Abstract][Full Text] [Related]
11. Myosin Activator Omecamtiv Mecarbil Increases Myocardial Oxygen Consumption and Impairs Cardiac Efficiency Mediated by Resting Myosin ATPase Activity.
Bakkehaug JP; Kildal AB; Engstad ET; Boardman N; Næsheim T; Rønning L; Aasum E; Larsen TS; Myrmel T; How OJ
Circ Heart Fail; 2015 Jul; 8(4):766-75. PubMed ID: 26025342
[TBL] [Abstract][Full Text] [Related]
12. Omecamtiv mercabil and blebbistatin modulate cardiac contractility by perturbing the regulatory state of the myosin filament.
Kampourakis T; Zhang X; Sun YB; Irving M
J Physiol; 2018 Jan; 596(1):31-46. PubMed ID: 29052230
[TBL] [Abstract][Full Text] [Related]
13. Improvement of cardiac function by a cardiac Myosin activator in conscious dogs with systolic heart failure.
Shen YT; Malik FI; Zhao X; Depre C; Dhar SK; Abarzúa P; Morgans DJ; Vatner SF
Circ Heart Fail; 2010 Jul; 3(4):522-7. PubMed ID: 20498236
[TBL] [Abstract][Full Text] [Related]
14. The effects of the cardiac myosin activator, omecamtiv mecarbil, on cardiac function in systolic heart failure: a double-blind, placebo-controlled, crossover, dose-ranging phase 2 trial.
Cleland JG; Teerlink JR; Senior R; Nifontov EM; Mc Murray JJ; Lang CC; Tsyrlin VA; Greenberg BH; Mayet J; Francis DP; Shaburishvili T; Monaghan M; Saltzberg M; Neyses L; Wasserman SM; Lee JH; Saikali KG; Clarke CP; Goldman JH; Wolff AA; Malik FI
Lancet; 2011 Aug; 378(9792):676-83. PubMed ID: 21856481
[TBL] [Abstract][Full Text] [Related]
15. Mechanistic and structural basis for activation of cardiac myosin force production by omecamtiv mecarbil.
Planelles-Herrero VJ; Hartman JJ; Robert-Paganin J; Malik FI; Houdusse A
Nat Commun; 2017 Aug; 8(1):190. PubMed ID: 28775348
[TBL] [Abstract][Full Text] [Related]
16. Omecamtiv mecarbil activates ryanodine receptors from canine cardiac but not skeletal muscle.
Nánási P; Gaburjakova M; Gaburjakova J; Almássy J
Eur J Pharmacol; 2017 Aug; 809():73-79. PubMed ID: 28506910
[TBL] [Abstract][Full Text] [Related]
17. Dilated cardiomyopathy mutation in the converter domain of human cardiac myosin alters motor activity and response to omecamtiv mecarbil.
Tang W; Unrath WC; Desetty R; Yengo CM
J Biol Chem; 2019 Nov; 294(46):17314-17325. PubMed ID: 31578282
[TBL] [Abstract][Full Text] [Related]
18. Cardiac Myosin Activator Omecamtiv Mecarbil: Novel Treatment for Systolic Heart Failure.
Mack M; Frishman WH
Cardiol Rev; 2024 Jul-Aug 01; 32(4):378-383. PubMed ID: 36946979
[TBL] [Abstract][Full Text] [Related]
19. Cardiac Myosin Activators in Systolic Heart Failure: More Friend than Foe?
Moin DS; Sackheim J; Hamo CE; Butler J
Curr Cardiol Rep; 2016 Oct; 18(10):100. PubMed ID: 27568794
[TBL] [Abstract][Full Text] [Related]
20. Population pharmacokinetic-pharmacodynamic modeling of omecamtiv mecarbil, a cardiac myosin activator, in healthy volunteers and patients with stable heart failure.
Vu T; Ma P; Xiao JJ; Wang YM; Malik FI; Chow AT
J Clin Pharmacol; 2015 Nov; 55(11):1236-47. PubMed ID: 25951506
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
